Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:physicist
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:KRAS
|
| gptkbp:affects |
gptkb:KRAS_protein
|
| gptkbp:analyzes |
biomarker discovery
longitudinal studies combination therapies |
| gptkbp:associated_with |
gptkb:healthcare_organization
|
| gptkbp:can_lead_to |
resistance to therapies
|
| gptkbp:caused_by |
activation of signaling pathways
|
| gptkbp:examines |
research studies
therapeutic strategies therapeutic efficacy clinical relevance |
| https://www.w3.org/2000/01/rdf-schema#label |
KRAS G13 D
|
| gptkbp:is_a |
oncogenic mutation
|
| gptkbp:is_aimed_at |
specific inhibitors
|
| gptkbp:is_analyzed_in |
molecular profiling
mutation frequency |
| gptkbp:is_associated_with |
tumor heterogeneity
tumor microenvironment adverse effects immune evasion chemotherapy resistance targeted therapy resistance |
| gptkbp:is_characterized_by |
glycine to aspartic acid substitution
|
| gptkbp:is_considered |
clinical decision-making
treatment planning |
| gptkbp:is_considered_as |
gptkb:Database_Management_System
|
| gptkbp:is_evaluated_by |
gptkb:municipality
|
| gptkbp:is_found_in |
human cancers
|
| gptkbp:is_involved_in |
cell differentiation
cell proliferation signal transduction cell survival angiogenesis |
| gptkbp:is_linked_to |
cellular metabolism
metastasis treatment outcomes poor prognosis |
| gptkbp:is_monitored_by |
gptkb:item
|
| gptkbp:is_often_used_in |
tumors
|
| gptkbp:is_part_of |
gptkb:KRAS_gene
Ras signaling pathway cancer therapy molecular diagnostics cancer research cancer biology precision medicine cancer genomics |
| gptkbp:is_recognized_by |
biopsy samples
|
| gptkbp:is_related_to |
tumorigenesis
|
| gptkbp:is_studied_in |
animal models
clinical trials drug development patient stratification |
| gptkbp:is_subject_to |
regulatory approval
|
| gptkbp:recognizes |
genetic testing
|
| gptkbp:reports_to |
gptkb:literary_work
|